Q-omics provides the consensus-scored SOX14 profile across patient tissues and cancer cell-line models. SOX14 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, SOX14 is differentially expressed in 8, with the highest sampling consensus in COAD. Additionally, SOX14 RNA expression shows 6,920 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UVM, COAD, and TGCT as cancer lineages where SOX14 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SOX14 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SOX14 survival associations across molecular data types. SOX14 RNA expression shows survival associations in the most cancer types (17), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SOX14 RNA expression–survival associations across cancer types. High SOX14 expression shows unfavorable associations in UVM, LIHC and DLBC, but favorable associations in OV, UCEC and STAD. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .021). Together, the overview and detailed table identify UVM as the clearest survival context for SOX14 RNA expression.
This table summarizes SOX14 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for SOX14. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SOX14 shows lower tumor expression in THCA and HNSC and higher tumor expression in COAD, STAD, UCEC and PRAD. The COAD box plot shows higher SOX14 RNA expression in tumor versus normal tissue (log2 FC = +2.341, t-test p < 0.001).
This table shows molecular features associated with SOX14 in patient tissues and cancer cell lines. In patient samples, SOX14 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, SOX14 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in OVARY and SOFT_TISSUE.
